CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics AG (CRSP) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has potential in its gene-editing pipeline and recent drug approval, the financial performance, negative revenue trends, and lack of significant trading signals suggest waiting for clearer signs of growth or stability before investing.
The MACD is positive but contracting, RSI is neutral at 49.845, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 57.175, with support at 53.454 and resistance at 60.896.
Approval of Casgevy, the first gene-editing drug for sickle cell disease and beta-thalassemia. Increased stake by Ark Innovation ETF, reflecting confidence in high-risk investments. Analysts maintain optimism about clinical updates and potential pipeline progress.
High treatment costs for Casgevy limit market revenue. Mixed analyst ratings and reduced price targets from some firms. No significant hedge fund or insider trading activity.
In Q4 2025, revenue dropped by 97.58% YoY to $864,000. Net income improved but remained negative at -$130.6 million, with EPS at -1.37. Gross margin remained at 100%. The company has sufficient cash reserves but struggles with financial losses.
Analyst ratings are mixed. Some firms, like Citi and Chardan, raised price targets and maintain Buy ratings, citing potential pipeline progress and Casgevy momentum. Others, like Morgan Stanley and JPMorgan, lowered price targets, citing limited revenue growth and financial challenges.
